兴科蓉医药2024 中期报告

2024INTERIM REPORT中期報告 Contents Corporate Information BOARD OF DIRECTORSExecutive Directors 20243 26 Mr. Huang Xiangbin(Chairman)Mr. Lei ShifengMr. Huang Zhijian (appointed with effect from 26 March 2024) Independent Non-executive Directors Mr. Lau Ying KitMr. Liu WenfangMr. Wang QingMr. Bai Zhizhong AUDIT COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Liu WenfangMr. Wang QingMr. Bai Zhizhong REMUNERATION COMMITTEE Mr. Wang Qing(Chairman)Mr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng NOMINATION COMMITTEE Mr. Huang Xiangbin(Chairman)Mr. Liu WenfangMr. Lau Ying Kit INTERNAL CONTROL AND CORPORATEGOVERNANCE COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Wang QingMr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng AUTHORISED REPRESENTATIVES Mr. Huang XiangbinMs. Peng Yunlu (appointed with effect from 26 March 2024)Mr. Li Kin Wai (resigned with effect from 26 March 2024) 20243 2620243 26 COMPANY SECRETARIES Ms. Peng YunluMr. Li Kin Wai (resigned with effect from 26 March 2024) 20243 26 REGISTERED OFFICE PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands Corporate Information (Continued) CORPORATE HEADQUARTERS E5-1805, Global CentreNo. 1700, North Section of Tianfu AvenueHigh-Tech Zone, ChengduSichuanPRC 1700E5-1805 PRINCIPAL PLACE OF BUSINESS IN HONG KONG Room 2403, Wing On Centre111 Connaught Road CentralHong Kong 1112403 CAYMAN ISLANDS PRINCIPAL SHAREREGISTRAR AND TRANSFER OFFICE Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 183171712 1716 Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17/F, Hopewell Centre,183 Queen’s Road EastWan ChaiHong Kong HONG KONG LEGAL ADVISERTian Yuan Law Firm LLP AUDITOR CL Partners CPA LimitedCertified Public AccountantsRegistered Public Interest Entity Auditor STOCK CODE ON THE MAIN BOARD OF THE STOCKEXCHANGE OF HONG KONG LIMITED 6833 COMPANY’S WEBSITEwww.sinco-pharm.com www.sinco-pharm.com 20163 10 LISTING DATE10 March 2016 Financial Highlights •Revenue of the Group increased by 40.1% or RMB436.8 million toRMB1,526.9 million for the Reporting Period (six months ended 30June 2023: RMB1,090.1 million), among which revenue from salesof pharmaceutical products increased by approximately RMB439.7million, while revenue from medical beauty services decreased byRMB2.9 million. •40.1%436.81,526.920236301,090.1439.72.9 •In line with the increase in the Group’s revenue, the gross profit ofthe Group increased by RMB20.7 million to RMB173.2 million forthe Reporting Period (six months ended 30 June 2023: RMB152.5million), while the gross profit margin decreased from 14.0% to11.3%, which was caused by the increase in the purchase cost dueto the deprecation of the RMB against the US$. •20.7173.220236 30152.514.0%11.3% •During the Reporting Period, the net profit increased byapproximately RMB4.3 million to RMB23.9 million (six months ended30 June 2023: RMB19.6 million). Such increase was mainly due tothe increase of the Group’s gross profit as stated above. •4.323.920236 3019.6 •During the Reporting Period, net profit attributable to owners ofthe Company amounted to RMB23.9 million (six months ended 30June 2023: RMB19.6 million), representing an increase in net profitattributable to owners of the Company by RMB4.3 million. •23.920236 3019.64.3 •Basic and diluted earnings per share amounted to RMB1.17 cent forthe Reporting Period (six months ended 30 June 2023: RMB0.965cent). •1.1720236 300.965 •20236 30 •The Board resolved not to declare any interim dividend for theReporting Period (six months ended 30 June 2023: Nil). Corporate Profile As a leading MPCM service provider with extensive experience in thedistribution of pharmaceutical imports, the Group focuses on bloodproducts and, based on nationwide marketing and promotion network,provides comprehensive MPCM services for small and medium-sizedoverseas pharmaceuticals manufacturers. The Group’s products areimported from well-known overseas pharmaceuticals manufacturerswith product portfolio centers on blood products as well as anti-infectivemedicine and other prescription medicine. The marketing and promotion services provided by the Groupinclude: coordinating and cooperating with overseas pharmaceuticalsmanufacturers in respect of import registration/re-registration and othermatters required by regulatory authorities; establishing customisedmarketing and promotion strategies based on the consideration of theproduct’s therapeutic areas and characteristics, regulatory environment,market demand and other commercial factors; selecting, appointing andmanaging third-party service promoters; holding academic conferences,lectures, seminars, and other promotional activities; and informing doctorsof the medical use